Intercept Pharmaceuticals (ICPT) PT Raised to $100 at Stifel
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts ICPT Hot Sheet
Price: $19.00 --0%
Rating Summary:
13 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Rating Summary:
13 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 23 | New: 12
Join SI Premium – FREE
Stifel analyst Derek C. Archila raised the price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $100.00 (from $99.00) while maintaining a Hold rating.
You May Also Be Interested In
- Fortune Brands (FBIN) PT Lowered to $58 at DA Davidson
- Viridian Therapeutic (VRDN) PT Raised to $43 at Stifel
- Gartner (IT) PT Raised to $220 at UBS
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
